Uterine Smooth Muscle Tumors: An Overview.

Journal

Advances in anatomic pathology

ISSN: 1533-4031

Titre abrégé: Adv Anat Pathol

Pays: United States

ID NLM: 9435676

Informations de publication

Date de publication:
19 Apr 2024

Historique:

medline: 22 4 2024

pubmed: 22 4 2024

entrez: 22 4 2024

Statut: aheadofprint

Résumé

Uterine smooth muscle tumors are a heterogeneous group of mesenchymal neoplasms with multiple histologic variants and distinct biological behaviors. Pathologic classification (benign, uncertain malignant potential, malignant) relies on the evaluation of mitotic index, necrosis, and degree of cytologic atypia, with different thresholds based on each subtype. Immunohistochemistry and other ancillary studies may be necessary to establish the diagnosis in a subset of cases, given the morphologic overlap with other mesenchymal neoplasms, including low-grade and high-grade endometrial stromal tumors, inflammatory myofibroblastic tumors, and PEComa. Recent advances in molecular diagnostics have refined the classification of smooth muscle tumors, but most cases are diagnosed purely on histologic grounds.

Identifiants

DOI: 10.1097/PAP.0000000000000446 PMID: 38647238

pubmed: 38647238

doi: 10.1097/PAP.0000000000000446

pii: 00125480-990000000-00103

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Déclaration de conflit d'intérêts

The authors have no funding or conflicts of interest to disclose.

Références

Board WE. Female Genital Tumours. IARC; 2020.

Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–107.

Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: A systematic review. BJOG. 2017;124:1501–1512.

Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355–364.

Stewart EA. Uterine fibroids. Lancet. 2001;357:293–298.

Merrill RM, Layman AB, Oderda G, et al. Risk estimates of hysterectomy and selected conditions commonly treated with hysterectomy. Ann Epidemiol. 2008;18:253–260.

Boyd C, McCluggage WG. Unusual morphological features of uterine leiomyomas treated with progestogens. J Clin Pathol. 2011;64:485–489.

Norris HJ, Hilliard GD, Irey NS. Hemorrhagic cellular leiomyomas (“apoplectic leiomyoma”) of the uterus associated with pregnancy and oral contraceptives. Int J Gynecol Pathol. 1988;7:212–224.

Nucci MR, O’Connell JT, Huettner PC, et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol. 2001;25:455–463.

Agoff SN, Grieco VS, Garcia R, et al. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol. 2001;9:164–169.

Busca A, Gulavita P, Parra-Herran C, et al. IFITM1 outperforms CD10 in differentiating low-grade endometrial stromal sarcomas from smooth muscle neoplasms of the uterus. Int J Gynecol Pathol. 2018;37:372–378.

Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: An immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14:465–471.

Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: A study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26:403–412.

Gargett CE, Bucak K, Zaitseva M, et al. Estrogen receptor-alpha and -beta expression in microvascular endothelial cells and smooth muscle cells of myometrium and leiomyoma. Mol Hum Reprod. 2002;8:770–775.

Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999;18:20–28.

Delgado B, Dreiher J, Braiman D, et al. P16, Ki67, P53, and WT1 expression in uterine smooth muscle tumors: An adjunct in confirming the diagnosis of malignancy in ambiguous cases. Int J Gynecol Pathol. 2021;40:257–262.

Zhang Q, Kanis MJ, Ubago J, et al. The selected biomarker analysis in 5 types of uterine smooth muscle tumors. Hum Pathol. 2018;76:17–27.

kuisma h, jokinen v, pasanen a, et al. histopathologic and molecular characterization of uterine leiomyoma-like inflammatory myofibroblastic tumor: Comparison to molecular subtypes of uterine leiomyoma. Am J Surg Pathol. 2022;46:1126–1136.

Makinen N, Kampjarvi K, Frizzell N, et al. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mol Cancer. 2017;16:101.

Mehine M, Kaasinen E, Makinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013;369:43–53.

Bennett JA, Weigelt B, Chiang S, et al. Leiomyoma with bizarre nuclei: A morphological, immunohistochemical and molecular analysis of 31 cases. Mod Pathol. 2017;30:1476–1488.

Croce S, Young RH, Oliva E. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases. Am J Surg Pathol. 2014;38:1330–1339.

Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: A review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol. 2010;17:91–112.

Keyhanian K, Lage JM, Chernetsova E, et al. Combination of MCM2 with Ki67 and p16 immunohistochemistry can distinguish uterine leiomyosarcomas. Int J Gynecol Pathol. 2020;39:354–361.

Mills AM, Ly A, Balzer BL, et al. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: Immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol. 2013;37:634–642.

Cao CD, Rico-Castillo J, De Cotiis D, et al. Digital quantification of Ki-67 and PHH3 in the classification of uterine smooth muscle tumors. Int J Gynecol Pathol. 2021;40:549–555.

Ubago JM, Zhang Q, Kim JJ, et al. Two subtypes of atypical leiomyoma: Clinical, histologic, and molecular analysis. Am J Surg Pathol. 2016;40:923–933.

Devereaux KA, Schoolmeester JK. Smooth muscle tumors of the female genital tract. Surg Pathol Clin. 2019;12:397–455.

O’Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol. 1990;21:223–227.

Joseph NM, Solomon DA, Frizzell N, et al. Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients. Am J Surg Pathol. 2015;39:1529–1539.

Rabban JT, Chan E, Mak J, et al. Prospective detection of germline mutation of fumarate hydratase in women with uterine smooth muscle tumors using pathology-based screening to trigger genetic counseling for hereditary leiomyomatosis renal cell carcinoma syndrome: A 5-year single institutional experience. Am J Surg Pathol. 2019;43:639–655.

Li H, Yang W, Tu X, et al. Clinicopathological and molecular characteristics of fumarate hydratase-deficient uterine smooth muscle tumors: A single-center study of 52 cases. Hum Pathol. 2022;126:136–145.

Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93:204–208.

Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:414–418.

Petrocelli R, Hindman N, Reinhold C. Current concepts in the imaging of uterine sarcomas. Radiol Clin North Am. 2023;61:627–638.

Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820–830.

Chapel DB, Nucci MR, Quade BJ, et al. Epithelioid leiomyosarcoma of the uterus: Modern outcome-based appraisal of diagnostic criteria in a large institutional series. Am J Surg Pathol. 2022;46:464–475.

parra-herran c, schoolmeester jk, yuan l, et al. myxoid leiomyosarcoma of the uterus: A clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms. Am J Surg Pathol. 2016;40:285–301.

Wang WL, Soslow R, Hensley M, et al. Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: A detailed analysis of 27 cases. Am J Surg Pathol. 2011;35:522–529.

Oliva E. Practical issues in uterine pathology from banal to bewildering: The remarkable spectrum of smooth muscle neoplasia. Mod Pathol. 2016;29(Suppl 1):S104–S120.

Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol. 2013;37:650–658.

Veras E, Zivanovic O, Jacks L, et al. Low-grade leiomyosarcoma” and late-recurring smooth muscle tumors of the uterus: A heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol. 2011;35:1626–1637.

Nucci MR, Webster F, Croce S, et al. Data set for reporting of uterine malignant and potentially malignant mesenchymal tumors: Recommendations from the international collaboration on cancer reporting (ICCR). Int J Gynecol Pathol. 2022;41:S44–S63.

Chapel DB, Sharma A, Lastra RR, et al. A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: An analysis of 203 cases. Mod Pathol. 2022;35:794–807.

Devins KM, Samore W, Nielsen GP, et al. Leiomyoma-like morphology in metastatic uterine inflammatory myofibroblastic tumors. Mod Pathol. 2023;36:100143.

Toledo G, Oliva E. Smooth muscle tumors of the uterus: A practical approach. Arch Pathol Lab Med. 2008;132:595–605.

Leitao MM Jr, Hensley ML, Barakat RR, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol. 2012;124:558–562.

Lee CH, Turbin DA, Sung YC, et al. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol. 2009;22:1519–1531.

Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: An immunohistochemical study. Appl Immunohistochem Mol Morphol. 2004;12:338–341.

D’Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol. 2009;40:1571–1585.

Schaefer IM, Hornick JL, Sholl LM, et al. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour. Histopathology. 2017;70:1138–1146.

Valencia-Guerrero A, Pinto A, Anderson WJ, et al. PNL2: A useful adjunct biomarker to HMB45 in the diagnosis of uterine perivascular epithelioid cell tumor (PEComa). Int J Gynecol Pathol. 2020;39:529–536.

Soslow RA. Melanocytic marker expression and TSC alterations/TFE3 fusions in uterine PEComas. Mod Pathol. 2022;35:449–450.

Chow KL, Tse KY, Cheung CL, et al. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: An outcome-based study. Histopathology. 2017;70:746–755.

Momeni-Boroujeni A, Yousefi E, Balakrishnan R, et al. Molecular-based immunohistochemical algorithm for uterine leiomyosarcoma diagnosis. Mod Pathol. 2023;36:100084.

Makinen N, Aavikko M, Heikkinen T, et al. Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12. PLoS Genet. 2016;12:e1005850.

Williams EA, Montesion M, Lincoln V, et al. HPV51-associated leiomyosarcoma: A novel class of TP53/RB1-wildtype tumor with predilection for the female lower reproductive tract. Am J Surg Pathol. 2022;46:729–741.

Williams EA, Sharaf R, Decker B, et al. CDKN2C-null leiomyosarcoma: A novel, genomically distinct class of TP53/RB1-wild-type tumor with frequent cic genomic alterations and 1p/19q-codeletion. JCO Precis Oncol. 2020;4:PO.20.00040.

Choi J, Manzano A, Dong W, et al. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A. 2021;118:e2025182118.

Chiang S, Samore W, Zhang L, et al. PGR gene fusions identify a molecular subset of uterine epithelioid leiomyosarcoma with rhabdoid features. Am J Surg Pathol. 2019;43:810–818.

Yoon JY, Marino-Enriquez A, Stickle N, et al. Myxoid smooth muscle neoplasia of the uterus: Comprehensive analysis by next-generation sequencing and nucleic acid hybridization. Mod Pathol. 2019;32:1688–1697.

Arias-Stella JA III, Benayed R, Oliva E, et al. Novel PLAG1 gene rearrangement distinguishes a subset of uterine myxoid leiomyosarcoma from other uterine myxoid mesenchymal tumors. Am J Surg Pathol. 2019;43:382–388.

Gupta M, Laury AL, Nucci MR, et al. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): A clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology. 2018;73:284–298.

Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535–558.

Travaglino A, Raffone A, Gencarelli A, et al. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP). Pathol Res Pract. 2021;226:153592.

Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): A clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009;33:992–1005.

Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27:326–332.

Perot G, Croce S, Ribeiro A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One. 2012;7:e40015.